LOS ANGELES , June 2, 2025 /PRNewswire/ -- The Schall Law Firm , a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Bakkt Holdings, Inc. ("Bakkt" or "the Company") (NYSE: BKKT) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 25, 2024 and March 17, 2025, inclusive (the "Class Period"), are encouraged to contact the firm before June 2, 2025.

SAN DIEGO , June 2, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of UroGen Pharma Ltd. (NASDAQ: URGN) securities between July 27, 2023 and May 15, 2025, both dates inclusive (the "Class Period"), have until July 28, 2025 to seek appointment as lead plaintiff of the UroGen class action lawsuit.

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / If you suffered a loss on your Krispy Kreme, Inc. (NASDAQ:DNUT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/krispy-kreme-inc-lawsuit-submission-form?prid=151249&wire=1&utm_campaign=15 or contact Joseph E. Levi, Esq.

atai Life Sciences (NASDAQ:ATAI, ETR:9VC) shares soared before Monday's opening bell after it announced it has inked a definitive agreement to merge with Beckley Psytech, a private clinical-stage biopharmaceutical company developing psychedelic-based therapies, in an all-share transaction valued at $390 million. The merger is contingent upon the achievement of pre-agreed success criteria in Beckley's ongoing Phase 2b trial of BPL-003 (mebufotenin benzoate), the company said.

WTKWY and ALX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on June 2, 2025.

Signet Jewelers Limited SIG will release its first-quarter earnings results before the opening bell on Tuesday, June 3.

Merck's (NYSE:MRK) top-selling drug – Keytruda's – impressive recent growth tells a compelling story, but it's one with a predictable ending. The pharmaceutical giant's remarkable performance is largely attributed to the phenomenal success of Keytruda, its blockbuster oncology drug.

Peter Boockvar, Bleakley Advisory Group CIO, joins 'Squawk Box' to discuss the latest market trends ahead of the opening bell on Monday.

CENTENNIAL, Colo.--(BUSINESS WIRE)--NUBURU, Inc. (NYSE American: BURU), a leader in high-power blue laser technology under a pivotal transformation plan, entered into a standby equity purchase agreement (the “Agreement”) with YA II PN, Ltd. (the “Investor”) under which the company has the option, subject to the conditions set forth therein, to sell up to $100 million in shares. This facility provides NUBURU with the financial flexibility to execute controlled stock sales until May 30, 2028. The.

HOUSTON--(BUSINESS WIRE)--Innovex expands platform with acquisition of Citadel Casing Solutions.

Brent crude rose 1.8% to over $65 a barrel on Monday afternoon after OPEC+ confirmed it would maintain a gradual approach to increasing oil supply. The news also gave a lift to energy stocks, with shares in Shell PLC (LSE:SHEL, NYSE:SHEL) and BP PLC (LSE:BP.

CRL and CHDI Foundation extend their Huntington's disease partnership, boosting integration and global flexibility in drug discovery.

Monarch Casino delivered a strong Q1 FY2025, gaining market share despite flat or declining regional gaming revenues and temporary renovation disruptions. The company's pristine balance sheet, no long-term debt, and robust free cash flow support continued dividends and buybacks, enhancing total shareholder return. With a $95 price target, I see 13.5% upside; including dividends and buybacks, total return could reach 16–17%, justifying a continued 'Buy' rating.

Chinese car companies have surged ahead of Ford Motor Co. (NYSE: F) in EV sales.

Given the uncertain environment, I continue to accumulate Schwab U.S. Dividend Equity ETF™, balancing my AI optimism with a need for defensive positioning. The market's aggressive risk appetite overlooks ongoing macro uncertainties, making a defensive allocation like SCHD increasingly prudent. SCHD isn't immune to market panic and has notable exposure to volatile energy prices, but its dividend consistency remains a key strength.

NEW YORK, NY / ACCESS Newswire / June 2, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Reddit, Inc. ("Reddit, Inc.") (NYSE:RDDT) concerning possible violations of federal securities laws. On May 21, 2024, before market open, Baird lowered its price target for Reddit to $120 from $140, citing concerns about artificial intelligence (AI) capabilities being utilized by tech powerhouses like Alphabet.

The midstream sector is under pressure. The YTD valuations have dropped across the board. Some, however, have been punished more than others.

REYKJAVIK, Iceland, June 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today its participation in the Jefferies Global Healthcare Conference 2025, which will be held in New York, New York June 3-5, 2025. Members of the management team will host one-on-one meetings at the conference. Dr. Balaji Prasad, Chief Strategy Officer will deliver a presentation with recent business updates at the conference on Thursday June 5, 2025, at 10:30 am-11:00 am EDT (14:30-15:00 GMT / 16:30-17:00 CET).

Fit-for-purpose Facility Will Provide Significant Operational Flexibility as the Company Continues to Execute on its Long-Term Growth Strategy Fit-for-purpose Facility Will Provide Significant Operational Flexibility as the Company Continues to Execute on its Long-Term Growth Strategy

WASHINGTON, June 02, 2025 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. NASDAQ: ASPI ("ASP Isotopes” or the “Company”), today announced the pricing of an underwritten registered direct offering of 7,518,797 shares of its common stock at a price of $6.65 per share to a single fundamental institutional investor. The gross proceeds from the offering, before deducting underwriting discounts and commissions and offering expenses, are expected to be approximately $50.0 million. The offering is expected to close on or about June 3, 2025, subject to the satisfaction of customary closing conditions.